Features Navigation

(800) 825-0224 Live Demo
 ID NQF # Measure Type High Priority Measure? NQS Domain Data Submission Method(s)
099 0391 Process Yes Effective Clinical Care Claims

Measure Description

Percentage of breast cancer resection pathology reports that include the pT category (primary tumor), thepN category (regional lymph nodes), and the histologic grade


This measure is to be submitted each time a breast cancer resection surgical pathology examination is performed during the performance period for breast cancer patients. Each unique CPT Category I code submitted on the claim will be counted for denominator inclusion. It is anticipated that eligible clinicians who examine breast tissue specimens following resection in a laboratory or institution will submit this measure. If the specimen is not primary breast tissue (e.g., liver, lung), report only CPT II code 3250F

NOTE: No notes related

Measure Submission

The listed denominator criteria is used to identify the intended patient population. The numerator quality-data codes included in this specification are used to submit the quality actions allowed by the measure. All measure specific coding should be submitted on the claim(s) representing the eligible encounter.


Reports that include the pT category, the pN category and the histologic grade


No data related

Numerator Quality-Data Coding Options

Denominator Exclusion: CPT II 3250F:
If Patient is not Eligible for this Measure because the Specimen is not Primary Breast Tissue (e.g., Liver, Lung) Report :

Specimen site other than anatomic location of primary tumor


Denominator Exclusion: 3260F with 1P:
pT Category, pN Category and Histologic Grade not Documented for Medical Reasons:

Append a modifier (1P) to CPT Category II code 3260F to report documented circumstances that appropriately exclude patients from the denominator.

Documentation of medical reason(s) for not including the pT category, the pN category, or the histologic grade in the pathology report (eg, re-excision without residual tumor, non-carcinomas)

Performance Met: CPT II 3260F:
pT Category, pN Category and Histologic Grade Documented

pT category (primary tumor), pN category (regionallymph nodes), and histologic grade documented in pathology report

Performance Not Met: 3260F with 8P:
pT Category, pN Category and Histologic Grade not Documented, Reason not Otherwise Specified:

Append a reporting modifier (8P) to CPT Category II code 3260F to report circumstances when the action described in the numerator is not performed and the reason is not otherwise specified.

pT category, pN category, and histologic grade were not documented in pathology report, reason not otherwise specified

NUMERATOR NOTE: No notes related


All breast cancer resection pathology reports (excluding biopsies)

Eligible cases are determined and must be reported, if either of the following conditions

Option 1 – Denominator Criteria (Eligible Cases):

Diagnosis for breast cancer (ICD-10-CM): C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.922, C50.929



Experience AdvancedMD Software in a Live Demo.

Schedule a short and personalized overview, guided by a live expert.

“Our workflow has diminished as far as the redundancies, having to do the back-and-click here or check on this and check on that—it’s all right there!”

Johnette Lamborne
Office manager

“Everybody still does basically the same thing; they just do it in a different and better way that’s more efficient.”

Steve Wampler, MD
Greenhill Family Clinic

Read the story  ›

“Having integrated practice management and EHR is absolutely wonderful, you don’t have to flip back and forth between systems—all of your information is at hand when needed.”

Raju Raval, MD

Read the story  ›

“We have seen approximately a three-fold improvement on a month-to-month basis of increased collections using AdvancedMD technology as compared to our previous technology provider. That has really been a step-change improvement with respect to the economics of the company.”

Michael Paul, CEO
Lineagen, Inc.